Exchange: NYSE·Updated 07:30 PM EST

QGEN News

News
all
press releases
Qiagen N.V. (NYSE:QGEN) Stock Now Rated "Hold" by Wall Street Brokerages
Qiagen N.V. (NYSE:QGEN - Get Free Report) has been given an average recommendation of "Hold" by the fifteen ratings firms that are covering the firm, Marketbeat.com reports. Eleven equities research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to...
MarketBeat
Qiagen N.V. (NYSE:QGEN) Stock Now Rated "Hold" by Wall Street Brokerages
Qiagen N.V. (NYSE:QGEN - Get Free Report) has been given an average recommendation of "Hold" by the fifteen ratings firms that are covering the firm, Marketbeat.com reports. Eleven equities research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to...
MarketBeat
More News
Review Qiagen's (QGEN) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
Zacks
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that shareholders overwhelmingly approved the appointment of Jonathan M. Pratt as a Managing Director and member of the QIAGEN Managing Board at an Extraordinary General Meeting of Shareholders. Jon Pratt joined QIAGEN as Chief...
Business Wire
Although the revenue and EPS for Qiagen (QGEN) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks
Qiagen (QGEN) delivered earnings and revenue surprises of +3.18% and +1.56%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced full results for the third quarter of 2026, with net sales and adjusted diluted earnings per share (EPS) ahead of the outlook. In line with preliminary results, Q3 2026 sales rose 3% to $548 million compared with Q3 2025, also...
Business Wire
Investors need to pay close attention to QGEN stock based on the movements in the options market lately.
Zacks
Protagonist Therapeutics (PTGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
Qiagen (QGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
Analysts downgraded Qiagen, Alcoa and Dutch Bros, cutting price targets for Qiagen to $52 and Dutch Bros to $46.read more...
Benzinga

Advertisement|Remove ads.